• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比伐卢定与肝素：这场较量远未结束？：疗效、安全性和成本仍是治疗ST段抬高型心肌梗死的战场。

Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction.

作者信息

Alexander Walter

出版信息

P T. 2015 Mar;40(3):209-17.

PMID:25798042
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4357354/
Abstract

A strident debate has been surging in the interventional cardiology community over the triumvirate of efficacy, safety, and cost of bivalirudin compared with heparin for anticoagulation of patients with ST-segment elevation myocardial infarction.

摘要

在介入心脏病学界，一场激烈的辩论正在激烈进行，内容是关于比伐卢定与肝素相比，用于ST段抬高型心肌梗死患者抗凝时在疗效、安全性和成本这三方面的情况。

相似文献

1
Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction.比伐卢定与肝素：这场较量远未结束？：疗效、安全性和成本仍是治疗ST段抬高型心肌梗死的战场。
P T. 2015 Mar;40(3):209-17.
2
Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.比伐卢定与肝素加糖蛋白 IIb/IIIa 抑制剂在经氯吡格雷预处理行经皮冠状动脉介入治疗的非 ST 段抬高型心肌梗死患者中的应用：来自 ACUITY 和 ISAR-REACT 4 试验的汇总分析。
Circ Cardiovasc Interv. 2012 Oct;5(5):705-12. doi: 10.1161/CIRCINTERVENTIONS.112.972869. Epub 2012 Oct 9.
3
Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.经桡动脉入路应用比伐卢定抗凝与肝素进行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者的结局：来自全国心血管数据注册中心的报告。
JACC Cardiovasc Interv. 2017 Jun 12;10(11):1102-1111. doi: 10.1016/j.jcin.2017.03.021. Epub 2017 May 17.
4
Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.普通肝素、依诺肝素或比伐卢定院前给药对接受ST段抬高型心肌梗死直接经皮冠状动脉介入治疗患者的疗效及安全性：来自ORBI注册研究的见解
Arch Cardiovasc Dis. 2016 Dec;109(12):696-707. doi: 10.1016/j.acvd.2015.10.007. Epub 2016 Nov 3.
5
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.阿昔单抗和肝素与比伐卢定用于非 ST 段抬高型心肌梗死。
N Engl J Med. 2011 Nov 24;365(21):1980-9. doi: 10.1056/NEJMoa1109596. Epub 2011 Nov 13.
6
Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.经皮冠状动脉介入治疗和 ST 段抬高型心肌梗死患者中比伐卢定与肝素加糖蛋白 IIb/IIIa 抑制剂比较的随机临床试验的荟萃分析。
Am J Cardiol. 2014 Jul 15;114(2):250-9. doi: 10.1016/j.amjcard.2014.04.033. Epub 2014 May 2.
7
Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.肝素单药治疗或比伐卢定在非 ST 段抬高型急性冠脉综合征或稳定型缺血性心脏病患者经皮冠状动脉介入治疗中的应用：来自药物洗脱支架和缺血事件评估登记研究的结果。
Circ Cardiovasc Interv. 2014 Jun;7(3):365-73. doi: 10.1161/CIRCINTERVENTIONS.113.001126. Epub 2014 Apr 15.
8
Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).比伐卢定与肝素用于非ST段抬高型和ST段抬高型心肌梗死的比较——基于瑞典心脏注册研究的随机临床试验（VALIDATE-SWEDEHEART试验）
Am Heart J. 2016 May;175:36-46. doi: 10.1016/j.ahj.2016.02.007. Epub 2016 Feb 20.
9
Bivalirudin in ST-segment-elevation myocardial infarction: for better or worse?比伐芦定用于ST段抬高型心肌梗死：是好是坏？
Expert Rev Cardiovasc Ther. 2015;13(8):893-5. doi: 10.1586/14779072.2015.1064311. Epub 2015 Jul 2.
10
Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.在ST段抬高型心肌梗死患者的直接经皮冠状动脉介入治疗中肝素与比伐卢定单药治疗的比较
Ann Pharmacother. 2016 Feb;50(2):141-51. doi: 10.1177/1060028015618206. Epub 2015 Dec 17.

引用本文的文献

1
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis.替格瑞洛联合比伐卢定在 PCI 治疗 STEMI 患者中的应用：一项系统评价和荟萃分析。
Am J Cardiovasc Drugs. 2024 May;24(3):385-398. doi: 10.1007/s40256-024-00636-6. Epub 2024 Apr 29.
2
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?凝血酶在急性冠状动脉综合征中作用的新研究方法：直接凝血酶抑制剂比伐卢定何去何从？
Molecules. 2016 Feb 27;21(3):284. doi: 10.3390/molecules21030284.

本文引用的文献

1
Choice of optimal anticoagulant to support primary PCI: out with the new, in with the old.
J Am Coll Cardiol. 2015 Jan 6;65(1):39-42. doi: 10.1016/j.jacc.2014.11.002.
2
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.比伐卢定与肝素联合或不联合糖蛋白 IIb/IIIa 抑制剂用于行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者：来自 HORIZONS-AMI 和 EUROMAX 试验的汇总患者水平分析。
J Am Coll Cardiol. 2015 Jan 6;65(1):27-38. doi: 10.1016/j.jacc.2014.10.029.
3
Real-time decision support to guide percutaneous coronary intervention bleeding avoidance strategies effectively changes practice patterns.实时决策支持以有效指导经皮冠状动脉介入治疗的出血避免策略，切实改变了实践模式。
Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):960-7. doi: 10.1161/CIRCOUTCOMES.114.001275. Epub 2014 Nov 4.
4
Bivalirudin started during emergency transport for primary PCI.比伐卢定在紧急转运行直接经皮冠状动脉介入治疗（PCI）期间开始使用。
N Engl J Med. 2013 Dec 5;369(23):2207-17. doi: 10.1056/NEJMoa1311096. Epub 2013 Oct 30.
5
Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).替奈普酶溶栓联合血管成形术与单独溶栓治疗急性心肌梗死的随机多中心临床试验 急性心肌梗死溶栓（TIMI）17 试验 急性 ST 段抬高型心肌梗死患者直接经皮冠状动脉介入治疗（直接 PCI）与溶栓后即刻补救性 PCI 随机临床试验 经皮冠状动脉介入治疗（PCI）后早期替罗非班对 ST 段抬高型心肌梗死患者的疗效和安全性的荟萃分析
J Am Coll Cardiol. 2014;63(1):15-20. doi: 10.1016/j.jacc.2013.09.027. Epub 2013 Oct 16.
6
Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.比伐卢定治疗与接受经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者临床及经济结局改善相关：一项观察性数据库研究结果
Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):52-61. doi: 10.1161/CIRCOUTCOMES.111.961938. Epub 2012 Jan 10.
7
The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction.比伐卢定对 ST 段抬高型心肌梗死治疗的成本和结局的影响。
Am Heart J. 2011 Sep;162(3):494-500.e2. doi: 10.1016/j.ahj.2011.05.019. Epub 2011 Jul 26.
8
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.肝素联合糖蛋白 IIb/IIIa 抑制剂与比伐卢定单药治疗以及紫杉醇洗脱支架与金属裸支架在急性心肌梗死（HORIZONS-AMI）中的应用：一项多中心随机对照临床试验的最终 3 年结果。
Lancet. 2011 Jun 25;377(9784):2193-204. doi: 10.1016/S0140-6736(11)60764-2. Epub 2011 Jun 12.
9
Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.美国一家医院在首次经皮冠状动脉介入治疗中改用比伐卢定的经济影响。
Hosp Pract (1995). 2010 Nov;38(4):138-46. doi: 10.3810/hp.2010.11.351.
10
Bivalirudin during primary PCI in acute myocardial infarction.急性心肌梗死直接经皮冠状动脉介入治疗中使用比伐卢定。
N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.